2024-519491-60-00RecruitingPhase 2
An open-label phase I/II, single-center, interventional singlearm basket trial of UKT-CART19.1 in patients with relapsed/refractory autoimmune diseases
Universitaetsklinikum Tuebingen AöR1 site in 1 country36 target enrollmentStarted: July 1, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 36
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
ZKS Tübingen
Scientific
Universitaetsklinikum Tuebingen AöR
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid TumorsAdvanced Solid Tumors2025-524857-15-00BeOne Medicines I GmbH24
Recruiting
Not Applicable
BG-C477-101Advanced Solid TumorsjRCT203125086018
Recruiting
Not Applicable
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsAdvanced Solid TumorsjRCT203125067815
Recruiting
Not Applicable
GNX1021-01Gastrointestinal cancerjRCT203126014164
Not yet recruiting
Phase 1
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy SubjectsMultiple sclerosis2025-521754-41-00Immunic AG24